Related references
Note: Only part of the references are listed.Infliximab in young paediatric IBD patients: it is all about the dosing
Maria M. E. Jongsma et al.
EUROPEAN JOURNAL OF PEDIATRICS (2020)
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
Hanna van Rheenen et al.
PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION (2020)
Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters
Ondrej Hradsky et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
David Drobne et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)
A. B. Friedman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Amy Hemperly et al.
CLINICAL PHARMACOKINETICS (2018)
Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience
Jennifer C. deBruyn et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2018)
Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve et al.
JOURNAL OF CROHNS & COLITIS (2018)
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial
X. Roblin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease An Observational Study
Zhang Fangbin et al.
MEDICINE (2016)
Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease
Victoria Grossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Concentrations of 6-Thioguanine Nucleotide Correlate With Trough Levels of Infliximab in Patients With Inflammatory Bowel Disease on Combination Therapy
Andres J. Yarur et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Monotherapy With Infliximab Versus Combination Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn Disease
Jaroslaw Kierkus et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2015)
Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease: A Meta-analysis
Amelie Carla Moreau et al.
INFLAMMATORY BOWEL DISEASES (2014)
Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study
Byron P. Vaughn et al.
INFLAMMATORY BOWEL DISEASES (2014)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
F. M. Ruemmele et al.
JOURNAL OF CROHNS & COLITIS (2014)
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
Arie Levine et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions
Dan Turner et al.
INFLAMMATORY BOWEL DISEASES (2012)
Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease
O. Pozler et al.
JOURNAL OF CROHNS & COLITIS (2010)
A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine
Mark E. Gerich et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Objective Versus Subjective Assessment of Oral Medication Adherence in Pediatric Inflammatory Bowel Disease
Kevin A. Hommel et al.
INFLAMMATORY BOWEL DISEASES (2009)
Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells
Ahmed F. Hawwa et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Initial Clinical Experience with Allopurinol-Thiopurine Combination Therapy in Pediatric Inflammatory Bowel Disease
Riad M. Rahhal et al.
INFLAMMATORY BOWEL DISEASES (2008)
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
Miles P. Sparrow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: A meta-analysis
MT Osterman et al.
GASTROENTEROLOGY (2006)
Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy
T Dervieux et al.
CLINICAL CHEMISTRY (2005)
Evaluation of the pediatric Crohn disease activity index: A prospective multicenter experience
J Hyams et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2005)
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants
E Schaeffeler et al.
PHARMACOGENETICS (2004)
Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
A Ansari et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2002)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)
Share Paper
